



MARYLAND MEDICAID PHARMACY PROGRAM

No. 69
Monday, June 29, 2009

ADVISORY

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) Maryland Pharmacy Program (MPP) has developed the Maryland Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MPP representative at 410-767-1455.

Changes in Mental Health Drugs Carve Out Effective July 1, 2009

- The Maryland Medicaid Mental Health Formulary Managed Care Carve-Out is being modified **effective July 1, 2009**. In the past, there were six drugs on the Mental Health Formulary that were not billed fee-for-service, even though these drugs were part of the drug classes that make up the Mental Health Formulary. These six drugs include all dosage forms of the following:
 - carbamazepine (Tegretol[®]) lamotrigine (Lamictal[®])
 - gabapentin (Neurontin[®]) topiramate (Topamax[®])
 - midazolam (Versed[®]) droperidol (Inapsin[®])
- Prescriptions for these six drugs with a date-of-service on or after July 1, 2009 for HealthChoice and Primary Adult Care (PAC) members must be billed fee-for-service, (BIN 610084, PCN DRMDPROD, Group ID MDMEDICAID), the same as all of the other drugs in the Mental Health Formulary.
- Effective July 1, 2001:
 - For HealthChoice members:
 - a \$1.00 co-payment for generic and preferred branded medications and a \$3 co-payment for branded medications will apply. No co-payment is required if the member is:
 - Younger than 21 years old,
 - Pregnant,
 - An inpatient in a long-term care facility.
 - The drug must be dispensed whether or not the member can afford the co-payment.

- For PAC members:
 - A \$2.50 co-payment for generic and preferred branded medications and a \$7.50 co-payment for branded medications will apply.
 - The drug may not be dispensed if the member does not pay the co-payment.
- Questions concerning this Advisory should be directed to the Division of Pharmacy Services at 410-767-1455.

Maryland Medicaid Mental Health Formulary

The following table reflects these changes and includes the mental health drugs which are carved out of the Managed Care Organization (MCO) pharmacy benefit effective July 1, 2009. Some of these drugs are subject to prior authorization requirements of the Preferred Drug List. Refer to <http://www.dhmf.state.md.us/mma/mpap/prefdruglist.html> for a complete listing of all drugs subject to preferred drug list requirements, or visit <http://www.epocrates.com/>. Click on "Epocrates Online" or "My Account" to register for your free Epocrates online account. Access to Epocrates is available online or through your personal computer or from a smart phone. The PDL is updated weekly.

All drugs from American Hospital Formulary Service (AHFS) therapeutic classes included in this table, including specific drugs that may not be listed in this table, are carved out of the MCO pharmacy benefit and are payable as fee-for-service through Maryland Medical Assistance, *unless otherwise noted*.

The following seven drugs, which may be used for some mental health indications, are not payable fee-for-service (unless otherwise noted) and are the responsibility of the HealthChoice MCOs for their enrollees, regardless of the prescriber.

Leuprolide acetate ⁺	Naltrexone	Liothyronine
Clonidine	Medroxyprogesterone ⁺	Disulfiram
Guanfacine		

⁺ When used for the treatment of adult males with certain diagnosed behavioral disorders, these two drugs will be paid fee-for-service, but will require preauthorization (PA) through the University of Maryland School of Pharmacy CAMP program at 410-706-3431.

Please note: Brand drugs which currently do not have a generic equivalent are listed by brand name in italics. Those drugs currently available generically are listed by generic name. Brand drugs, which are available as multi-source generics, require prior approval and completion of a Maryland Medwatch Form unless otherwise noted on the Maryland Medicaid Preferred Drug List. Brand name drugs are in italic print.

Therapeutic Class	Drug
Anticholinergic Agents AHFS Class No. 283608	benztropine trihexyphenidyl
Benzodiazepines (Anticonvulsants) AHFS Class No. 281208	clonazepam
Miscellaneous Anticonvulsants AHFS Class No. 281292	<i>Banzel</i> carbamazepine <i>Felbatol</i> gabapentin <i>Gabitril</i> <i>Keppra XR</i> lamotrigine levetiracetam <i>Lyrica</i> oxcarbazepine <i>Stavzor</i> topiramate valproate/divalproex <i>Vimpat</i> zonisamide
Antidepressants AHFS Class No. 281604	amitriptyline amoxapine <i>Aplenzin</i> bupropion bupropion SR bupropion XL citalopram clomipramine

Cymbalta - Clinical criteria apply see
<http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm>

desipramine

doxepin

Effexor XR

fluoxetine

fluvoxamine

imipramine

Luvox CR

Lexapro

maprotiline

Marplan

mirtazapine

mirtazapine Soltab

Nardil

nefazodone

nortriptyline

Parnate

paroxetine

Paxil CR

Pexeva

Pristiq

protriptyline

Prozac Weekly

Sarafem

Savella

sertraline

	<p><i>Surmontil</i></p> <p><i>Symbyax</i></p> <p>trazodone</p> <p>venlafaxine</p> <p><i>Venlafaxine ER</i></p>
--	--

<p>Antipsychotic Agents</p> <p>AHFS Class No. 281608</p>	<p><i>Abilify</i></p> <p>chlorpromazine</p> <p>clozapine</p> <p><i>FazaClo</i></p> <p>fluphenazine</p> <p><i>Geodon</i></p> <p>haloperidol</p> <p><i>Invega</i></p> <p>loxapine</p> <p><i>Moban</i></p> <p><i>Orap</i></p> <p>perphenazine</p> <p>risperidone</p> <p><i>Risperdal Consta</i></p> <p><i>Risperdal M-Tab</i></p> <p><i>Seroquel</i></p> <p><i>Seroquel XR</i></p> <p><i>Symbyax</i></p> <p>thioridazine</p> <p>thiothixene</p> <p>trifluoperazine</p>
--	---

	<p><i>Zyprexa</i>- Clinical criteria apply see http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm</p> <p><i>Zyprexa Zydis</i>- Clinical criteria apply see http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm</p>
<p>Amphetamines</p> <p>AHFS Class No. 282004</p>	<p>amphetamine/dextroamphetamine XR</p> <p>amphetamine</p> <p><i>Desoxyn</i></p> <p>dextroamphetamine</p> <p>methamphetamine</p> <p><i>Vyvanse</i></p>
<p>Anorexigenic Agents and Respiratory and Cerebral Stimulants (Anorexigenic Agents are not covered)</p> <p>AHFS Class No. 282092</p>	<p><i>Concerta</i></p> <p><i>Daytrana</i></p> <p><i>Focalin</i></p> <p><i>Focalin XR</i></p> <p><i>Metadate CD</i></p> <p>methylphenidate</p> <p><i>Provigil</i></p> <p><i>Ritalin LA</i></p>
<p>Anxiolytics, Sedatives and Hypnotics – Benzodiazepines</p> <p>AHFS Class No. 282408</p>	<p>alprazolam</p> <p>chlordiazepoxide</p> <p>clorazepate</p> <p><i>Diastat</i></p> <p>diazepam</p> <p><i>Doral</i></p> <p>estazolam</p> <p>flurazepam</p> <p>lorazepam</p> <p>midazolam</p>

	<p>oxazepam</p> <p><i>Restoril 7.5 mg</i></p> <p><i>Restoril 22.5 mg</i></p> <p>temazepam</p> <p>triazolam</p>
<p><i>Miscellaneous Anxiolytics, Sedatives and Hypnotics</i></p> <p><i>AHFS Class No. 282492</i></p>	<p><i>Ambien CR</i></p> <p>bupirone</p> <p>chloral hydrate</p> <p>droperidol</p> <p>hydroxyzine</p> <p><i>Lunesta</i></p> <p>meprobamate</p> <p><i>Rozerem</i></p> <p>zaleplon</p> <p>zolpidem</p> <p><i>Zolpimist</i></p>
<p>Antimanic Agents</p> <p>AHFS Class No. 282800</p>	<p>lithium</p>
<p>Central Nervous Systems Agents Misc.</p> <p>AHFS Class No. 289200</p>	<p><i>Strattera</i> – Clinical criteria apply see http://www.dhmh.state.md.us/mma/mpap/clinicalcriteria.htm</p> <p><i>Strattera</i> is the only drug carved out fee-for-service in this AHFS drug class.</p>
<p>MAO Inhibitors</p> <p>AHFS Class No. 283632</p>	<p><i>Emsam</i></p> <p><i>Emsam</i> is the only drug carved out fee-for-service in this AHFS drug class</p>